Decoy Therapeutics Inc.
For the period ended Dec 31, 2024. Filed Mar 21, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 21, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
March 21, 2025 SALARIUS PHARMACEUTICALS, INC.
By: /s/ David J. Arthur
David J. Arthur
President & Chief Executive Officer
Each of the undersigned officers and directors of Salarius Pharmaceuticals, Inc., hereby constitutes and appoints David J. Arthur and Mark J. Rosenblum, their true and lawful attorney-in-fact and agent, for them and in their name, place and stead, in any and all capacities, to sign their name to any and all amendments to this Annual Report on Form 10-K, and other related documents, and to cause the same to be filed with the Securities and Exchange Commission, granting unto said attorneys, full power and authority to do and perform any act and thing necessary and proper to be done in the premises, as fully to all intents and purposes as the undersigned could do if personally present, and the undersigned for himself hereby ratifies and confirms all that said attorney shall lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this annual report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated
| SIGNATURE | TITLE | DATE |
|---|---|---|
| /s/ William K. McVicar William K. McVicar | Chairman of the Board | March 21, 2025 |
| /s/ David J. Arthur David J. Arthur | Director, President & Chief Executive Officer (Principal Executive Officer) | March 21, 2025 |
| /s/ Mark J. Rosenblum Mark J. Rosenblum | Executive Vice President of Finance and Chief Financial Officer( Principal Financial Officer and Principal Accounting Officer) | March 21, 2025 |
| /s/ Tess Burleson Tess Burleson | Director | March 21, 2025 |
| /s/ Arnold HanishArnold Hanish | Director | March 21, 2025 |
| /s/ Paul Lammers Paul Lammers | Director | March 21, 2025 |
| /s/ Jon Lieber Jon Lieber | Director | March 21, 2025 |
| /s/ Bruce McCreedy Bruce McCreedy | Director | March 21, 2025 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.